← Back to Search

Sodium Channel Blocker

Ranolazine for Coronary Artery Disease (REMS Trial)

Phase 4
Waitlist Available
Led By Narendra Singh, MD
Research Sponsored by Atlanta Heart Specialists, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to 6 months
Awards & highlights

Summary

The purpose of this study is to measure the effect of ranolazine on ETT (exercise treadmill test) exercise duration in four ethnic subgroups with established coronary artery disease and risk factor(s) for the metabolic syndrome: Caucasian, African American, Southeast Asian and East Indian.

Eligible Conditions
  • Coronary Artery Disease
  • Metabolic Syndrome
  • Angina

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Exercise Duration
Secondary study objectives
Angina Pectoris
Pharmaceutical Preparations
HgbA1c
+2 more

Trial Design

2Treatment groups
Active Control
Group I: Standard of CareActive Control1 Intervention
Group II: RanolazineActive Control1 Intervention
Ranolazine in addition to standard of care medical therapy

Find a Location

Who is running the clinical trial?

Atlanta Heart Specialists, LLCLead Sponsor
Gilead SciencesIndustry Sponsor
1,098 Previous Clinical Trials
860,309 Total Patients Enrolled
18 Trials studying Coronary Artery Disease
8,744 Patients Enrolled for Coronary Artery Disease
Narendra Singh, MDPrincipal InvestigatorAtlanta Heart Specialists, LLC
2 Previous Clinical Trials
112 Total Patients Enrolled
~11 spots leftby Sep 2025